MDMG ANNOUNCES START OF CONSTRUCTION OF LAPINO-4

By

Regulatory News | 29 Dec, 2020

Updated : 08:01

RNS Number : 9385J
MD Medical Group Investments PLC
29 December 2020
 

 



 

 

MD Medical Group AnnouncES THE START OF CONSTRUCTION OF LAPINO-4

29 December 2020, Moscow - MD Medical Group Investments Plc ("MD Medical Group", "MDMG" or the "Company" - MDMG), a leading Russian private healthcare provider announces the start of construction of a new multifunctional hospital ("Lapino-4") on the Lapino medical complex grounds.

The construction of the new hospital designed primarily for treatment of coronavirus patients during the pandemic is being done using rapid construction technology. The hospital will have 100 beds. Cumulative investment in the project amounts to 800 million rubles. It is planned that the new hospital will start receiving patients in the first quarter of 2021.

Mark Kurtser, CEO of MD Medical Group, said: "Soon after the inauguration of the "Lapino-2" surgical hospital due to the second wave of the pandemic we were obliged to fully convert it into receiving COVID-19 patients. From the beginning of October 2020 and till today the Lapino-2 hospital is operating with a 100% utilization. By opening another new hospital, we will be able to return to the initial specialization of "Lapino-2", where a state-of-the-art oncology centre offering a full cycle medical service on a high level with adherence to modern world protocols will resume work. At the present moment our new multidisplinary oncological service, which also operates at full strength, is temporarily based at the "Lapino-1" hospital and it is limited in its possibilities to receive patients. After returning to "Lapino-2" it will use its potential fully".     

 

This announcement contains inside information.

 

For further information please contact:

Investors

Media

           

Dmitry Yakushkin

MD Medical Group Investments Plc

+7 (495) 139-87-40,  ext. 16329 
d.yakushkin@mcclinics.ru

EM

Tom Blackwell: +7 919 102 9064

Sergii Pershyn: +1 929 855 8188

MDMG@em-comms.com

 

 

 

 

 

 

 

About MD Medical Group

 

MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 42 modern healthcare facilities, including 6 hospitals and 36 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov-on-Don.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

Since November 9, 2020 the Company's GDRs are traded also on the Moscow Exchange. Quotation is done in Russian Rubles.

 

Forward-Looking Statements:

 

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFFFFFLTFII

Last news